The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 24, 2025

Filed:

Mar. 24, 2021
Applicant:

Dynamiker Biotechnology (Tianjin) Co, Ltd., Binhai New Area Tianjin, CN;

Inventors:

Chunlong Liu, Binhai New Area Tianjin, CN;

Zhou Zhang, Binhai New Area Tianjin, CN;

Shaohua Ma, Binhai New Area Tianjin, CN;

Jiashun Wang, Binhai New Area Tianjin, CN;

Yan Su, Binhai New Area Tianjin, CN;

Zeqi Zhou, Binhai New Area Tianjin, CN;

Assignee:

Dynamiker Biotechnology (Tianjin) Co., Ltd., Binhai New Area Tianjin, CN;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/569 (2006.01); G01N 21/76 (2006.01); G01N 33/532 (2006.01); G01N 33/543 (2006.01); G01N 33/563 (2006.01);
U.S. Cl.
CPC ...
G01N 33/56983 (2013.01); G01N 21/76 (2013.01); G01N 33/532 (2013.01); G01N 33/54326 (2013.01); G01N 33/563 (2013.01); G01N 2469/20 (2013.01);
Abstract

The present application provides a novel coronavirus antibody detection kit based on magnetic particle chemiluminescence. The detection kit includes: streptavidin magnetic particles, biotin-labeled novel coronavirus antigens, an acridine sulfonamide-labeled secondary antibody, a sample diluent and a quality control material; wherein the biotin-labeled novel coronavirus antigens include a recombinant nucleocapsid protein and a recombinant spike protein S1. The sample to be tested, the biotin-labeled antigens and the streptavidin magnetic particles are mixed, incubated and washed, and then the acridine sulfonamide-labeled antibody is added to form a magnetic particle-streptavidin-biotin-antigen-novel coronavirus antibody-secondary antibody complex, and then the luminous intensity is detected to qualitatively determine the sample to be tested.


Find Patent Forward Citations

Loading…